Avricore Health Inc experienced a remarkable surge in its stock price, driven by significant developments in its business strategy.
Yesterday, Avricore Health Inc (AVCR.V) saw its stock price soar by 27.27%, closing at CA$0.07. This impressive gain reflects investor optimism following the company's recent announcement of a collaboration with Abbott for point-of-care testing in the UK.
Advertisement
Avricore Health Inc
AVCR.V
AVCR.V
Avricore Health Inc
WealthAwesomeMarket cap
$6.95M
52W high
$0.10
52W low
$0.04
1W change
+27.27%
Beta
0.32
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AVCR's historical volatility
30-Day Vol
145.8%
Annualized
90-Day Vol
121.1%
Annualized
Trend (90d)
+31.1%
Annualized drift
90d Mean
C$0.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.07 | C$0.04 – C$0.12 |
| 60 trading days | C$0.08 | C$0.04 – C$0.15 |
| 90 trading days | C$0.08 | C$0.03 – C$0.19 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The surge in Avricore Health's stock emphasizes the potential impact of strategic partnerships in the healthcare sector, particularly in expanding access to innovative testing solutions.
Avricore Health Inc stock up 27.27%
The stock's significant increase reflects strong market interest and confidence in the company's growth prospects following its strategic collaboration.
Bull case
The partnership with Abbott is a key moment for Avricore Health. It allows the company to tap into Abbott's established presence in the UK healthcare market, which could lead to increased revenue and wider use of HealthTab™ technology.
Bear case
Even with this positive momentum, investors should stay cautious. The healthcare sector is facing challenges, including broader market declines that could affect sentiment. There are also execution risks tied to the partnership that might impact future performance.
Advertisement
Key Developments Driving Growth
Avricore Health's recent announcement about its partnership with Abbott is a game-changer. This agreement enables HealthTab™ to distribute Abbott's Afinion™ 2 Analyzer in NHS-linked pharmacies, improving access to essential health testing. This collaboration not only marks a significant milestone for Avricore Health but also meets the rising demand for efficient healthcare solutions.
Market Response and Future Outlook
The market's positive reaction to Avricore Health's announcement shows strong investor confidence in the company's growth strategy. However, with the healthcare sector facing challenges, including a general decline in healthcare stocks, it will be crucial for Avricore to execute its plans effectively to maintain this momentum. Investors should keep a close eye on the company's performance as it navigates this partnership.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
